Apoptosis, a Metabolic "Head-to-Head" between Tumor and T Cells: Implications for Immunotherapy

• Published in: Cells (Basel, Switzerland) Switzerland), 2024-05, Vol.13 (11), p.924
• Main Authors: Franzese, Ornella, Ancona, Pietro, Bianchi, Nicoletta, Aguiari, Gianluca
• Format: Article
• Language: English
• Subjects: Animals; Antimitotic agents; Antineoplastic agents; Apoptosis; Cancer; Cancer therapies; Cell death; Cytochrome; Cytotoxicity; Development and progression; Health aspects; Homeostasis; Humans; Immune response; Immune system; Immunogenicity; Immunosuppressive agents; Immunosurveillance; Immunotherapy; Immunotherapy - methods; Kinases; Lymphocytes; Lymphocytes T; Metabolism; Metastasis; Neoplasms - immunology; Neoplasms - pathology; Neoplasms - therapy; Phagocytes; Proteins; Review; T cells; T-Lymphocytes - immunology; Tofacitinib; Tumor cells; Tumor microenvironment; Tumor Microenvironment - immunology; Tumors
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells13110924

Induction of apoptosis represents a promising therapeutic approach to drive tumor cells to death. However, this poses challenges due to the intricate nature of cancer biology and the mechanisms employed by cancer cells to survive and escape immune surveillance. Furthermore, molecules released from apoptotic cells and phagocytes in the tumor microenvironment (TME) can facilitate cancer progression and immune evasion. Apoptosis is also a pivotal mechanism in modulating the strength and duration of anti-tumor T-cell responses. Combined strategies including molecular targeting of apoptosis, promoting immunogenic cell death, modulating immunosuppressive cells, and affecting energy pathways can potentially overcome resistance and enhance therapeutic outcomes. Thus, an effective approach for targeting apoptosis within the TME should delicately balance the selective induction of apoptosis in tumor cells, while safeguarding survival, metabolic changes, and functionality of T cells targeting crucial molecular pathways involved in T-cell apoptosis regulation. Enhancing the persistence and effectiveness of T cells may bolster a more resilient and enduring anti-tumor immune response, ultimately advancing therapeutic outcomes in cancer treatment. This review delves into the pivotal topics of this multifaceted issue and suggests drugs and druggable targets for possible combined therapies.